compound semaglutide | C187H291N45O59 | CID 56843331 Semaglutide

In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]

Bcl-2, B-cell lymphoma 2

Local Care

Individual responses vary based on genetics, metabolism, and how quickly doses increase

With such reductions, projections show that the industry is expected to be hit with as much as 3% reduction in sales

The enhancement of active endogenous GLP-1 leads to increased insulin but reduced glucagon secretion, in addition to delaying gastric emptying and supressing appetite ( Pathophysiology of T2D is characterized by predominant insulin resistance than impaired insulin secretion in Caucasians whereas impaired insulin secretion rather than insulin resistance predominates in Asians ( It is apparent that the therapeutic effects of DPP-IV inhibitors in Asians are more pronounced compared with Caucasians